Edwards Lifesciences announces the US and European launches of its Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve, designed to enhance implantation in the challenging mitral position. The launch will take place at the 24th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).
The Magna Mitral Ease valve incorporates new features to facilitate access, placement and suturing during both conventional and minimally invasive heart valve surgeries, especially those using a thoracotomy. Its product enhancements, such as the tri-coloured holder, unique suture guide line, wide saddle shaped cuff and new accessories are all designed for easier implantation. Magna Mitral Ease is based on the clinically proven and durable Edwards PERIMOUNT mitral valve design. Patients with tissue valves such as Magna Mitral Ease minimise the need for the lifelong prescription of blood thinners and its associated risks.
“Magna Mitral Ease can help us to achieve continuous improvements in the treatment of patients by maintaining the excellent hemodynamics of its predecessor, while improving and simplifying mitral valve implantation,” said prof. Jan Gummert.
At Saturday’s EACTS TechnoCollege, Dr Malakh Shrestha, provided a preliminary, single centre case presentation on Edwards’ investigational, minimally invasive, rapid deployment Odyssey aortic valve platform. This initial series of aortic valve replacement procedures using the Odyssey platform demonstrated an approximately 50% reduction in bypass and cross-clamp times when compared to conventional, isolated aortic valve surgery. The Odyssey platform is currently being studied in Europe as part of the TRITON trial, and additional data are expected to be announced after enrolment and patient follow up is complete.
“The Odyssey platform is designed to simplify and facilitate minimally invasive aortic valve surgery, thereby enabling shorter cardiopulmonary bypass times due to its unique implantation method. We believe these procedural enhancements may also improve patient outcomes,” said Donald E. Bobo.